Author:
Gascon-Gimenez F.,Teruel-Casasus A.,Domínguez-Morán J.A.,Láinez J.M.
Subject
General Earth and Planetary Sciences,General Engineering,General Environmental Science
Reference11 articles.
1. Ocrevus. Ficha técnica. Ámsterdam: Agencia Europea de Medicamentos; 2021. Disponible en: https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_es.pdf
2. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature;Zanetta;J Neurol Sci.,2020
3. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis;Cohen;Neurology.,2019
4. Non-late-onset neutropaenia following treatment of multiple sclerosis with ocrelizumab;Alba Suárez;Neurologia.,2021
5. Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab;Auer;Mult Scler Relat Disord.,2020